Faculty Collaboration Database

Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation. J Neurooncol 1992 Jun;13(2):151-5

Date

06/01/1992

Pubmed ID

1432032

DOI

10.1007/BF00172764

Scopus ID

2-s2.0-0026734805 (requires institutional sign-in at Scopus site)   21 Citations

Abstract

We report here the first known case of a patient with recurrent metastatic medulloblastoma to achieve long-term disease-free survival following treatment with allogeneic bone marrow transplantation. A 27 year old white male with recurrent metastatic medulloblastoma involving lymph nodes, bone and bone marrow was treated with multi-agent chemotherapy followed by allogeneic bone marrow transplantation from an HLA-identical sibling donor. Morbidity was acceptable with moderate to severe mucositis in the immediate post transplant period and clinical grade I graft versus host disease of the skin controlled with modest doses of corticosteroids. The patient continues in unmaintained complete remission in excess of 28 months with a performance status of 100%. Allogeneic marrow transplantation following cytoreductive salvage chemotherapy is an aggressive strategy that may offer an improved likelihood of disease eradication and ultimate cure for poor prognosis patients with recurrent metastatic medulloblastoma.

Author List

Lundberg JH, Weissman DE, Beatty PA, Ash RC

Author

Joel Lundberg MD Adjunct Assistant Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow Purging
Bone Marrow Transplantation
Bone Neoplasms
Brain Neoplasms
Combined Modality Therapy
Cyclophosphamide
Etoposide
Graft vs Host Disease
Humans
Lymphatic Metastasis
Male
Medulloblastoma
Prevalence
Remission Induction
Salvage Therapy
Transplantation, Homologous
Vincristine